The European Medicines Agency is expected to decide on a marketing authorization (MA) for Wegovy in the cardiovascular field by April, reports Bloomberg.

The application has been submitted to the EMA and also to the FDA, which has granted priority review.

The challenge for Novo Nordisk today is mainly to increase its production capacity to meet the strong demand for its product, which is already widely used in diabetic patients, but also to treat obesity, says Invest Securities.

' As a reminder, in August 2023, Novo Nordisk shares rose sharply after an advanced clinical trial showed a 20% reduction in the risk of cardiovascular events in obese patients treated with semaglutide ' stresses the analyst firm.

' In addition, at the end of 2023, a Ph III trial was stopped prematurely on interim analysis by the DSMB committee due to a high probability of success on the primary efficacy endpoint, which was to demonstrate the benefit of semaglutide on the progression of chronic kidney disease in type 2 diabetes (T2DM) patients with CKD ' adds Invest Securities.

Copyright (c) 2024 CercleFinance.com. All rights reserved.